Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.Through the acquisition of this respiratory disease-focused company, Merck will add Ohtuvayre (ensifentrine), a first-in-class, selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its cardiovascular and pulmonary pipeline and portfolio.Also Read: Rege ...

Company Participation in Conferences - Verona Pharma's senior management will participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York, NY [1] - The company will also be present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami, FL [1] - Webcasts of each conference presentation will be available on the company's website [1] Company Overview - Verona Pharma is a biopharmaceutical company focused on developing therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, Ohtuvayre (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3]

Verona Pharma plc (NASDAQ: VRNA ) is just three quarters into the launch of its chronic obstructive pulmonary disease (COPD) drug Ohtuvayre (ensifentrine), but the blockbuster drug discussion doesn't seem farfetched. When I last covered the nameScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disc ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quar ...